Share

2026 Data Catalyst Award Call for Applications

Share

We are excited to announce the 2026 Data Catalyst Award! This award helps offset the cost of RNA profiling experiments for academic researchers. This year’s award prioritizes miRNA biology projects, though applications across RNA biology are welcome. 

Selected researchers receive assistance from Eclipsebio to offset the cost of using assays from our RNA profiling portfolio, including miR-eCLIP+. The scope of the funding depends on the project. You keep full ownership of your experimental data. Control datasets generated during your project are de-identified and contributed to our eVERSE database, where they will support both basic research and drug discovery across our partner network. 

To apply, fill out the application below. You will be asked in the application to submit a brief description of your miRNA scientific or therapeutic goals. If you pass the initial review, you will meet with our design team to review your project in more detail before final selection.

For any questions about the Data Catalyst Award, application process, or how Eclipsebio supports our partners in their research and drug discovery programs, you can contact us at info@eclipsebio.com

*To support early-stage innovation, this competition is only available to academic or non-profit researchers.

Latest news

2026 Data Catalyst Award Call for Applications

The Data Catalyst Award helps offset the cost of RNA profiling experiments using Eclipsebio's assays from our RNA profiling portfolio and contributes to the eVERSE database.

Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development

Eclipsebio's eCOMPASS platform combines AI-optimized design and sequencing-based analytics to produce successful RNA therapeutics efficiently.

2026 mRNA Innovators Award Call for Applications

The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics

Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]